ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2026
Early detection of gastric cancer via multiplex blood assay targeting CfDNA methylation signatures.
Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundHigh heterogeneity of gastric cancer (GC) drives cellular diversity. This complicates liquid biopsies, as detecting tumor markers in bodily fluids may not fully represent the tumor due to uneven marker distribution, compromising test accuracy and sensitivity.
methodsIntegrative analysis of 43 paired tissues, TCGA, and GEO databases identified 24 key GC-specific DMPs. Combined analysis with cfDNA bisulfite sequencing (79 normal controls and 70 GC) revealed four GC-specific DMPs. We developed GC-mqMSP using cfDNA from 70 normal controls, 106 GC, 41 lung cancer, and 23 colorectal cancer patients, was further validated in an independent cohort (45 GC and 13 normal controls). dCas9-Tet1-CD targeted demethylation assessed functional roles in GC development.
resultBased on four GC-specific DMPs common to both tissue and cfDNA, we developed an efficient and convenient GC-mqMSP assay for detection. This assay demonstrated the ability to distinguish early-stage GC patients from normal controls and specifically differentiated GC patients from those with other tumors, achieving an AUCs (0.932 and 0.927), sensitivity (90.54% and 84.38%), and specificity (83.67% and 90.48%) in the training and validation sets. We selected ZNF154 for further study for the high coefficient weights of its two DMPs (Cg05661282 and Cg03234186). DNMT1/UHRF1 complex bind to promoting their hypermethylation and suppressing ZNF154 expression. Hypermethylation of Cg05661282 and Cg03234186 facilitated GC cell proliferation, migration, and tumor formation both in vitro and in vivo. Targeted demethylation at these DMPs reversed tumorigenesis and progression.
conclusionA cfDNA methylation-based integrated score was constructed in this study to predict GC in patients clinically.
Indexed as
Identifiers
41359088What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.